During the past decade, Southern Clinical Research / ID # 611 conducted 2 clinical trials. In the 10-year time frame, 2 clinical trials started and 0 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 2 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

According to Clinical.Site data, the most researched conditions in "Southern Clinical Research / ID # 611" are "Endometriosis" (2 trials). Many other conditions were trialed in "Southern Clinical Research / ID # 611" in a lesser frequency.

Most popular intervention types in "Southern Clinical Research / ID # 611" are "Drug" (2 trials). Other intervention types were less common.

The name of intervention was led by "200 mg linzagolix tablet" (2 trials), "75 mg linzagolix tablet" (2 trials), "Add-back capsule (E2 1 mg / NETA 0.5 mg)" (2 trials), "Placebo capsule to match Add-back capsule" (2 trials) and "Placebo tablet to match 200 mg linzagolix tablet" (2 trials). Other intervention names were less common.

The vast majority of trials in "Southern Clinical Research / ID # 611" are 2 trials for "Female" genders.

Currently, there are NaN active trials in "Southern Clinical Research / ID # 611". undefined are not yet recruiting, undefined are recruiting, 1 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 1 completed trials in Southern Clinical Research / ID # 611, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Southern Clinical Research / ID # 611, 0 "Phase 1" clinical trials were conducted, 0 "Phase 2" clinical trials and 2 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".